Abstract
Cerebral venous thrombosis (CVT) is a rare venous thrombotic event. We review our local experience in the management of CVT in comparison to other venous thromboembolism (VTE) with specific focus on risk factors for thrombotic recurrence. Retrospective evaluation of consecutive CVT presentations from January 2005 to June 2015, at two major tertiary hospitals in Northeast Melbourne, Australia. This population was compared to a separate audit of 1003 consecutive patients with DVT and PE. Fifty-two patients (30 female, 22 male) with a median age of 40 (18–83) years, presented with 53 episodes of CVT. Twenty-nine episodes (55 %) were associated with an underlying risk factor, with hormonal risk factors in females being most common. The median duration of anticoagulation was 6 months with 11 receiving life-long anticoagulation. Eighty-one percent had residual thrombosis on repeat imaging, which was not associated with recurrence at the same or distant site. Nine (17 %) had CVT-related haemorrhagic transformation with two resultant CVT-related deaths (RR 22.5; p = 0.04). All three VTE recurrences occured in males with unprovoked events (RR 18.2; p = 0.05) who were subsequently diagnosed with myeloproliferative neoplasm (MPN). Compared to the non-cancer VTE population, non-cancer CVT patients were younger, had similar rate of provoked events and VTE recurrence, although with significantly higher rate of MPN diagnosis (RR 9.30 (2.29–37.76); p = 0.002) CVT is a rare thrombotic disorder. All recurrences in this audit occurred in male patients with unprovoked events and subsequent diagnosis of MPN, suggesting further evaluation for MPN may be warranted in patients with unprovoked CVT.
Similar content being viewed by others
References
Bousser MG, Ferro JM (2007) Cerebral venous thrombosis: an update. Lancet Neurol 6:162–170
Coutinho JM, Zuurbier SM, Aramideh M et al (2012) The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke 43:3375–3377
Ferro JM, Canhão P, Stam J et al (2004) Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35:664–670
Lauw MN, Barco S, Coutinho JM et al (2013) Cerebral venous thrombosis and thrombophilia: a systematic review and meta-analysis. Semin Thromb Hemost 39:913–927
Dentali F, Poli D, Scoditti U et al (2012) Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 10:1297–1302
World Health Organization. International statistical classification of diseases and related health problems, 10th revision. http://apps.who.int/classifications/icd10/browse/2010. Accessed 7 October 2013
Bamford JM, Sandercock PA, Warlow CP et al (1989) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 20:828
(2015) Special Issue: Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis, June 20–25, 2015. J Thromb Haemost 13(Supplement S2):1–997
Rodeghiero F, Tosetta A, Abshire T et al (2010) ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 8:2063–2065
Coutinho JM, Stam J, Canhão P et al (2015) Cerebral venous thrombosis in the absence of headache. Stroke 46:245–247
Ferro JM, Canhão P, Stam J et al (2009) Delay in the diagnosis of cerebral vein and dural sinus thrombosis: influence on outcome. Stroke 40:3133–3138
Saposnik G, Barinagarrementeria F, Brown RD Jr et al (2011) Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:1158–1192
Coutinho J, de Brunkin SF, deVeber G et al (2012) Anticoagulation for cerebral venous sinus thrombosis. Stroke 43:e41–e42
Tait C, Baglin T, Watson H et al (2012) Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol 159:28–38
Thorell S, Parry-Jones A, Punter M et al (2015) Cerebral venous thrombosis—A primer for the haematologist. Blood Rev 29:45–60
Coutinho J, Ferro J, Canhão P et al (2009) Cerebral venous and sinus thrombosis in women (ISCVT). Stroke 40:2356–2361
Piazza G (2012) Cerebral venous thrombosis. Circulation 125:1704–1709
Moll S, Waldron B (2014) Cerebral and Sinus Vein Thrombosis. Circulation 130:e68–e70
Ferro J, Canhão P (2008) Complications of cerebral vein and sinus thrombosis. Front Neurol Neurosci 23:161–171
Terni E, Giannini N, Chiti N et al (2015) Cerebral sinus venous thrombosis: clinical and pathogenetic perspectives from Tuscany. Blood Coagul Fibrinolysis 26:505–508
Martinelli I, De Stefano V, Carobbio A et al (2014) Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study. Am J Hematol 89:e200–e205
Dentali F, Ageno W, Rumi E et al (2014) Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. Thromb Res 134:41–43
Passamonti S, Biguzzi E, Cazzola M et al (2012) The JAK2 V617F mutation in patients with cerebral venous thrombosis. J Thromb Haemost 10:998–1003
Geisbusch C, Richter D, Herweh C et al (2014) Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients. Stroke 45:2469–2471
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None to declare.
Rights and permissions
About this article
Cite this article
Lim, H.Y., Ng, C., Donnan, G. et al. Ten years of cerebral venous thrombosis: male gender and myeloproliferative neoplasm is associated with thrombotic recurrence in unprovoked events. J Thromb Thrombolysis 42, 423–431 (2016). https://doi.org/10.1007/s11239-016-1362-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-016-1362-3